 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2021, vol. 27, issue3
Subject Area: Medicine
-
DOI: 10.5272/jimab.2021273.3868
Published online: 05 August 2021
Original article
J of IMAB. 2021 Jul-Sep;27(3):3868-3872
PILOT STUDY ON THE INCIDENCE OF BREAST CANCER AMONG THE POPULATION OF THE NORTH EAST REGION OF BULGARIA
Antoaneta Tsvetkova
,
Medical College, Medical University - Varna, Bulgaria.
ABSTRACT:
Purpose: According to the Bulgarian National Cancer Registry of 2017, breast cancer accounted for 26.8% of all malignancies among women. The actual incidence rate was 108.1 per 100 000.
Materials/ Methods: An observational retrospective study was conducted among breast cancer patients diagnosed and treated at Dr Marko Markov Specialised Hospital for Treatment of Oncologic Diseases (SHTOD) - Varna, between 2016 and 2019. Descriptive statistics and collected data included demographic characteristics, clinical data (survival rates) and type of pharmacotherapy.
Results: In terms of gender distribution, significantly more women were affected, accounting for approximately 99.05%. Patients from cities were almost 7 times more than those from villages. Patients aged between 61 and 70 represented the largest number, which accounted for 28.04% of all included in the study.
Conclusion: Taking into consideration not only the efficiency but also the cost-effectiveness of available treatment strategies can lead to considerably better therapeutic outcomes. There is no pharmacoeconomic data analysis in Bulgaria. A further study of all direct and indirect costs is required in order to estimate the cost of premature death, reduced working capacity and disability.
Keywords: breast cancer, incidence, North East region of Bulgaria, BNCR, NHIF,
- Download FULL TEXT /PDF 510 KB/
Please cite this article as: Tsvetkova A. Pilot Study on the incidence of breast cancer among the population of the North East region of Bulgaria. J of IMAB. 2021 Jul-Sep;27(3):3868-3872. DOI: 10.5272/jimab.2021273.3868
Correspondence to: Antoaneta Tsvetkova, Medical University - Varna, Medical College – Varna; 84 Tsar Osvoboditel Blvd , Varna, Bulgaria; E-mail: antoaneta.tsvetkova11@gmail.com
REFERENCES:
1. State of Health in the EU. Bulgaria: Country Health Profile 2017. European Commission. [Internet]
2. [Roche Bulgaria: Breast cancer. HER2-negative breast cancer] [in Bulgarian] rochemd.bg. 27. 11. 2020. [Internet]
3. Breast cancer statistics: World Cancer Research Fund. 2018 [Internet]
4. [Healthcare 2018.] [in Bulgarian] NSI, Sofia. 2019.
5. [Breast cancer incidence in Bulgaria, 2014 & 2015.] [in Bulgarian] BNCR. [Internet]
6. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. Atlanta: American Cancer Society. 2019. [Internet]
7. [Annual report of the Municipality of Varna.] [in Bulgarian] [Internet]
8. [Pharmacotherapeutic guideline for oncology diseases in Bulgaria.] [in Bulgarian] 2019. [Internet]
9. [ICD-10 C50 Malignant neoplasm of breast.] [in Bulgarian] Mediately. [Internet]
10. [Annual report on the activities of the National Health Insurance Fund for 2019.] [in Bulgarian] NHIF Sofia. 2020. [Internet]
11. [Our treatment of cancer is more costly than in Germany.] [in Bulgarian] Clinica.bg. [Internet]
12. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society. 2017. [Internet]
13. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5): E359-86. [PubMed]
14. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42. [PubMed]
15. Hormone Therapy More Cost-Effective Than Chemotherapy for Patients With HR+/HER2- Metastatic Breast Cancer. JCP Editors. J Clin Pathways. 2016; 2(4):10-13. [Internet]
16. Dimitrova M, Lakic D, Petrova G, Bešlija S, Culig J. Comparative analysis of the access to healthcare services and breast cancer therapy in 10 Eastern European countries. SAGE Open Med. 2020 May 20;8:2050312120922029. [PubMed]
17. Mihaylova S. [Synthesis and Biological Evaluation of SMAC-NT Peptide Conjugates with Combined Antineoplastic and Analgesic Effect.] [Dissertation] Varna (Bulgaria): Medical University-Varna. 2019. 3p. [in Bulgarian] [Internet]
18. Michailova S, Georgieva M, Bruckdorfer T, Pajpanova T. Influence of arginine mimetics on the biological effects of NT(8-13) analogues. European Peptide Society & PSP. 2018; 257-258. [Crossref]
19. Michailova S, Dzimbova T, Kalikova K, Tesarova E, Pajpanova T. Chemical stability of new neurotensin (8-13) analogues. Bulg Chem Commun. 2017; 49(E):113–117. [Internet]
20.Georgiev K, Radeva M, Balacheva A, Michaylova S, Pajpanova T. Modulation of CYP3A4 by the RGD- and Neurotensin(8-13)-analogues. European Peptide Society & PSP. 2018. pp.215-216. [Crossref]
21. Public Health. Non-communicable diseases. Cancer. European Commission. [Internet]
Received: 02 February 2021
Published online: 05 August 2021